Success Metrics

Completion Rate
0%(0/1)
Active Trials
3(75%)
Terminated
1(25%)

Phase Distribution

Ph not_applicable
1
25%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Terminated(1)

Detailed Status

Recruiting2
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
3
Success Rate
0.0%
Most Advanced
N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

recruiting250%
terminated125%
active_not_recruiting125%

Recent Activity

3 active trials
Showing 4 of 4
recruiting

Metastatic Leiomyosarcoma Biomarker Protocol

NCT05653388
active_not_recruiting

Multiomics Approach in Metastatic Clear Renal Cell Carcnoma

NCT05782400
recruitingnot_applicable

Predictive Value of Soluble CD146 in Glioblastoma Patients

NCT06001281
terminated

Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere®

NCT03203837

Clinical Trials (4)

Showing 4 of 4 trials
NCT05653388

Metastatic Leiomyosarcoma Biomarker Protocol

Recruiting
NCT05782400

Multiomics Approach in Metastatic Clear Renal Cell Carcnoma

Active Not Recruiting
NCT06001281Not Applicable

Predictive Value of Soluble CD146 in Glioblastoma Patients

Recruiting
NCT03203837

Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere®

Terminated

All 4 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
4